# US 2006/0079479 A1 · Methods of inducing vasodilation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079479 A1
- Document ID: US20060079479A1
- Status: Published application
- Kind: A1
- Application number: 11/226,626
- Filed: 2005-09-14
- Published: 2006-04-13
- Earliest claimed: 2004-10-13
- Inventors: Italo Biaggioni
- Web page: https://patentgrep.com/patent/US20060079479A1

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods of inducing vasodilation in a subject diagnosed with a need for vasodilation, comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is not in need of anesthesia, analgesia, sedation, or iatrogenic hypothermia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is not in need of treatment for stress or pathologic hypothermia.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 5 (depends on 4)

The method of claim 4, wherein the mammal is a human.

### Claim 6 (depends on 1)

The method of claim 1, wherein the blood vessel is a venule or vein.

### Claim 7 (depends on 1)

The method of claim 1, wherein the blood vessel is an arteriole or artery.

### Claim 8 (depends on 7)

The method of claim 7, wherein the blood vessel is immediately proximate to a vascular bed.

### Claim 9 (depends on 8)

The method of claim 8, wherein adenosine monophosphate is administered in a dosage of from about 5 μg to about 100 μg.

### Claim 10 (depends on 9)

The method of claim 9, wherein adenosine monophosphate is administered in a dosage of about 30 μg.

### Claim 11 (depends on 1)

The method of claim 1, wherein adenosine monophosphate is administered in a concentration of from about 0.05 mg/ml to about 400 mg/ml.

### Claim 12 (depends on 11)

The method of claim 11, wherein adenosine monophosphate is administered in a concentration of from about 0.5 mg/ml to about 50 mg/ml.

### Claim 13 (depends on 12)

The method of claim 12, wherein adenosine monophosphate is administered in a concentration of about 10 mg/ml.

### Claim 14 (depends on 1)

The method of claim 1, wherein adenosine monophosphate is administered in a dosage of from about 10 μg per kg of bodyweight per minute to about 240 μg per kg of bodyweight per minute.

### Claim 15 (depends on 14)

The method of claim 14, wherein adenosine monophosphate is administered in a dosage of about 180 μg per kg of bodyweight per minute.

### Claim 16 (depends on 1)

The method of claim 1, wherein adenosine monophosphate is administered in a dosage of from about 1 mg to about 16 mg.

### Claim 17 (depends on 16)

The method of claim 16, wherein adenosine monophosphate is administered in a dosage of about 8 mg.

### Claim 18 (depends on 1)

The method of claim 1, wherein adenosine monophosphate is administered at a rate of from about 0.5 mg/minute to about 5 mg/minute.

### Claim 19 (depends on 18)

The method of claim 18, wherein adenosine monophosphate is administered at a rate of about 3 mg/minute.

### Claim 20

A method of inducing vasodilation in a human diagnosed with a need for vasodilation comprising administering into a blood vessel of the human a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the human.

### Claim 21

A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, wherein the blood vessel is not a coronary artery, whereby the administration of the composition induces vasodilation in the subject.

### Claim 22

A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine and adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject.

### Claim 23

A method of inducing vasodilation in a subject diagnosed with a need for vasodilation comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate and lidocaine in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation in the subject.
